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Objectives. This study sought to determine whether omega-3
fatty acids act as hypertension prophylaxis in heart transplant
recipients and have an impact on vascular reactivity.
Background. Cyclosporine-induced hypertension is probably
related to endothelial dysfunction. Suggested vasodilatory mech-
anisms of omega-3 fatty acids may therefore be particularly
beneficial in heart transplant recipients.
Methods. Heart transplant recipients were randomized to
receive either 4 g of omega-3 fatty acids (treatment group, n 5 14)
daily or corn oil (placebo group, n 5 14) from the fourth
postoperative day. Twenty-four hour blood pressure monitoring
was performed at day 12 and 1, 2, 3 and 6 months postoperatively.
Microvascular endothelium-dependent vasodilation, evaluated by
skin laser Doppler perfusion measurements of postocclusive
reactive hyperemia, was determined preoperatively and at the end
of the study.
Results. With comparable characteristics at the time of ran-
domization, blood levels of cyclosporine did not at any point differ
between the groups. After 6 months, systolic blood pressure
decreased 2 6 4 mm Hg (mean 6 SEM) in the treatment group
and increased 17 6 4 mm Hg in the placebo group (p < 0.01),
whereas diastolic blood pressure increased 10 6 3 and 21 6
2 mm Hg (p < 0.01), respectively. The decrease in systolic blood
pressure was inversely proportional to increases in concentrations
of serum eicosapentaenoic and docosahexaenoic acid (p 5 0.01).
After 6 months, five patients in the treatment group and nine in
the placebo group needed additional antihypertensive treatment.
Although the endothelial-dependent phase of the reactive hyper-
emic response remained unchanged in the treatment group, it
decreased significantly in the placebo group.
Conclusions. Postoperative daily administration of 4 g of
omega-3 fatty acids in heart transplant recipients is effective as
hypertension prophylaxis, depending on increases in serum eico-
sapentaenoic and docosahexaenoic acids. Preservation of micro-
vascular endothelial function, demonstrated by a more pro-
nounced response to forearm skin ischemia in the treatment
group, may contribute to the hypotensive role of omega-3 fatty
acids.
(J Am Coll Cardiol 1997;29:1324–31)
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Hypertension is a common complication in cyclosporine treat-
ment. In heart transplant recipients it is present among 60% to
100% of patients (1), and optimal control is often difficult to
achieve. Evident within a few weeks postoperatively, it is
characterized by normal central hemodynamic variables and
increased systemic vascular resistance. The underlying mecha-
nisms of peripheral vasoconstriction are unknown, but recent
reports suggest (2–5) a dysfunctional endothelium with an
imbalance of local mediators of vasoconstriction and vasodila-
tion.
Omega-3 fatty acids have favorable metabolic effects that
may protect against cardiovascular disease. Evidence of im-
proved vascular reactivity, due to changes in the prostanoid
profile or enhanced release of nitric oxide (6,7), suggests
particular usefulness in cyclosporine-induced hypertension.
Although a hypotensive effect has been questioned, two recent
meta-analyses (8,9) indicate a significant but modest effect on
blood pressure in hypertensive patients. A recent study (10) in
hypertensive heart transplant recipients treated with omega-3
fatty acids for 12 weeks also demonstrated a significant reduc-
tion in blood pressure.
We therefore performed a randomized, double-blind,
placebo-controlled study to assess whether prophylactic ad-
ministration of omega-3 fatty acids prevents hypertension in
cyclosporine-treated heart transplant recipients. To improve
the accuracy and provide additional information on the diurnal
pattern of blood pressure, the effect was evaluated by 24-h
ambulatory monitoring. The impact of omega-3 fatty acids on
endothelium-dependent vasodilation was assessed by examina-
tion of the postocclusive hyperemic response.
Methods
Patients. Thirty consecutive orthotopic heart transplant
recipients were randomized to receive either 4 capsules/day of
highly concentrated ethyl esters of omega-3 fatty acids (Oma-
cor, Pronova AS, Oslo, Norway) (treatment group) or an equal
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amount of an ethyl ester of corn oil (placebo group). The soft
gelatin capsule in the treatment group contains 1 g of fatty
acids (46.5% eicosapentaenoic acid and 37.8% docosahexa-
enoic acid), whereas 3.7 mg of alpha-tocopherol as antioxidant
was added to both the active treatment and placebo capsules.
All patients gave written informed consent. They were in-
structed to refrain from cod-liver oil during the study, which
was approved by the Regional Ethics Committee.
Treatment was started 4 days postoperatively and continued
for 6 months. Compliance was ascertained by capsule counts
and determination of serum phospholipid fatty acids. All the
patients received a triple immunosuppressive regimen of cy-
closporine, azathioprine and prednisolone. Cyclosporine was
initiated immediately preoperatively at a dose of 6 mg/kg body
weight and tapered off according to the department rejection
protocol. Azathioprine was given at 2 mg/kg per day and
prednisolone at 0.2 mg/kg per day and tapered off to 0.1 mg/kg
per day over 2 months. Rejection was treated with boluses of
methylprednisolone (Solu-Medrol, Pharmacia & Upjohn,
Puurs, Belgium) and, if necessary, rabbit anti-thymocyte glob-
ulin (Thymoglobuline, Pasteur Merieux, Lyon, France).
Blood pressure monitoring. Twenty-four hour blood pres-
sure monitoring was performed with an Accutracker 2, Sun-
tech model 104 device (Suntech Medical Instruments) using
the R wave gated auscultatory method. Blood pressure was
measured four times every hour during the day (7 AM to 11 PM)
and twice every hour during the night (11 PM to 7 AM). Eighty
readings were attempted during each recording session. The
average number of readings accepted for evaluation was equal
in the two groups and fell from 95% to 88% during follow-up,
probably reflecting more disturbances from increasing physical
activity. Two recording sessions with .20% technical errors
were excluded. Recordings were analyzed by personal com-
puter (Accusoft, Suntech Medical Instruments).
Each patient underwent 24-h measurements at day 12 and
1, 2, 3 and 6 months postoperatively. Recordings earlier than
day 12 were complicated by the unstable postoperative state
and the extensive use of pacemakers, the latter preventing
simultaneous blood pressure monitoring with the ambulatory
device. As reference values, we adopted the mean 24-h systolic
and diastolic limits proposed by the meta-analysis of Staessen
et al. (11), and patients with probable hypertension
(.139/87 mm Hg for 24 h) were considered for antihyperten-
sive treatment with enalapril. In these patients, medication was
withheld for 48 h before the next recording and discontinued if
the recording was normotensive due to the unstable postoper-
ative hemodynamic situation and the possible accumulating
hypotensive effect of omega-3 fatty acids.
Changes in blood pressure load were derived from the area
under the mean arterial blood pressure curve at day 12 and 6
months postoperatively. The day and night periods were
computed separately and combined to form the 24-h area
under the curve. Threshold values used for calculation were
107 and 93 mm Hg for day and night, respectively, derived
from systolic and diastolic values of 140/90 and 120/80 (one
third of the pulse pressure added to the diastolic blood
pressure).
Measurements of reactive hyperemia. Skin-reactive hyper-
emia was determined using a laser Doppler flowmeter (Peri-
flux, model PF3, Perimed Ltd., Ja¨rfa˙lla, Sweden) (12), which
produces a voltage signal proportional to microvascular perfu-
sion (13). After 20 min of acclimatization in a quiet room with
constant air temperature (22 6 1°C), laser Doppler perfusion
measurements were performed on the pulp of the left third
finger with the patients in a supine position. Digital skin
temperature was recorded with an electronic thermometer
(Grant Instruments, Cambridge, UK). After measurement of
basal perfusion, 3 min of suprasystolic pressure occlusion
(280 mm Hg) of the left forearm was followed by a sudden
release of the cuff. Rest perfusion level, peak hyperemic
response and duration of reactive hyperemia were recorded
(Fig. 1). In addition, perfusion debt repayment was also
calculated, defined as the area under the perfusion curve
versus time until return of the signal to preocclusion baseline
levels.
Laboratory evaluations. Trough levels of cyclosporine
were determined by a fluorescence polarization immunoassay
method 12 h after the last dose of the drug. Serum lipids were
determined after overnight fasting before the start and at the
end of the study. Total cholesterol and triglycerides were
analyzed by standard enzymatic calorimetric methods, whereas
high density lipoprotein (HDL) cholesterol was determined in
the supernatant after precipitation with phosphotungstic acid
and magnesium chloride. The phospholipid acids were quan-
tified by gas chromatography. Creatinine clearance was mea-
sured before and 6 months after transplantation.
Statistics. Data are expressed as mean value 6 SEM.
One-way analysis of variance with repeated measurements was
used for multiple intragroup analysis. Multivariate analysis of
variance followed by the Newman Keuls test was used for
multiple time comparisons between the two groups. The
Mann-Whitney U test was applied for unpaired statistical
analysis and Wilcoxon signed-rank test for paired results. The
Pearson correlation test was used for correlation analysis. A
value ,0.05 was considered statistically significant.
Results
Patients. Of the 30 patients who entered the study, 14 in
each group were studied for 6 months. One patient in each
group died of vascular rejection 7 and 8 weeks postoperatively
and were therefore excluded from the total analyses. There
were no significant differences between the two groups for any
of the recorded characteristics (Table 1). One patient in the
treatment group and three in the placebo group experienced
Abbreviations and Acronyms
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
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minor strokes. The gelatin capsules were well tolerated, and
mild abdominal complaints were comparable between the
groups.
Blood pressure. Twenty-four hour blood pressure mea-
surements at baseline were higher in the treatment group than
in the placebo group (134/73 6 5/3 vs. 126/70 6 5/2 mm Hg,
respectively, p , 0.05 for systolic blood pressure). In the
treatment group, a slight fall in systolic values of 2 6 4 mm Hg
and a diastolic increase averaging 10 6 3 mm Hg was observed
from baseline to 6 months postoperatively. By contrast, a
significant and consistent increase in mean systolic and dia-
stolic blood pressure at all time intervals took place in the
placebo group, averaging 17 6 4/21 6 2 mm Hg from baseline
to 6 months postoperatively; both changes were significantly
higher (p , 0.01) than in the placebo group (Fig. 2). Except for
changes in diastolic blood pressure at 1 month, the increase in
both systolic and diastolic blood pressure was significantly
lower at each 24 h registration in the treatment group (p ,
0.01).
Figure 3 shows the 24-h mean arterial blood pressure
profiles of the two groups at baseline and at 6 months. The
placebo group reveals a greater and more persistent increase in
24-h blood pressure after 6 months. The calculated increase in
the 24-h hypertensive load from baseline to 6 months, esti-
mated as changes in the area under the mean arterial blood
pressure curves with threshold values for hypertension as
indicated in Figure 3, was also significantly lower in the
treatment group (60 6 28 vs. 149 6 35 mm Hg, p , 0.05). The
higher blood pressure in the treatment group at baseline was
due to a less pronounced nocturnal dip and a steeper rise in the
early morning hours. The percent nocturnal reductions in
systolic and diastolic blood pressure were 1 6 2% and 6 6 3%
in the treatment group and 7 6 2% and 8 6 3% in the placebo
group, respectively. The corresponding nocturnal reductions
after 6 months were 11 6 2% and 14 6 4% versus 8 6 3% and
9 6 3%, respectively. The attenuated rise in blood pressure in
the treatment group was observed throughout the 24-h period
after 6 months.
After 6 months, five patients in the treatment group and
nine in the placebo group needed additional antihypertensive
treatment. Using the 24-h blood pressure criteria mentioned
earlier, the mean treatment group blood pressure values of
135/85 6 5/4 mm Hg were within normotensive limits, whereas
140/89 6 4/3 mm Hg in the placebo group indicates systolic
and diastolic hypertension.
Reactive hyperemia. Three patients underwent heart trans-
plantation before preoperative reactive hyperemia could be
Table 1. Characteristics of Recipients and Donors in the Two
Study Groups
Placebo Group
(n 5 14)
Treatment Group
(n 5 14)
Donor
Age (yr) 33 6 3 29 6 2
% male 85 73
Cold ischemic time (min) 121 6 11 96 6 18
Warm ischemic time (min) 52 6 5 55 6 6
Recipient
Age (yr) 53 6 6 48 6 10
% male 73 73
Body mass index (kg/m2) 23.3 6 0.7 24.2 6 0.8
Creatinine clearance (ml/min) 55 6 4 57 6 5
Previous hypertension (no. of pts) 4 3
Etiology of HF (no. of pts)
Cardiomyopathy 3 5
Coronary heart disease 11 9
Data presented are mean value 6 SEM, unless otherwise indicated; no
significant differences were found between the groups. HF 5 heart failure; pts 5
patients.
Figure 1. Representative example of
postocclusive reactive hyperemia taken
from a continuous recording using la-
ser Doppler perfusion measurements.
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measured. Before transplantation, the levels of skin rest per-
fusion, peak reactive hyperemia, time to recovery from the
hyperemic response and the perfusion debt repayment area did
not differ between the two groups (Table 2). Skin temperature
at this point and at 6 months postoperatively was also similar
(treatment group vs. placebo group: 32.3 6 0.4 vs. 31.0 6 0.8°C
and 32.8 6 0.4 vs. 33.2 6 0.5°C, respectively). Peak hyperemic
levels were significantly improved in both groups 6 months
postoperatively. However, whereas the time required for the
hyperemic perfusion to return to preocclusive levels increased
slightly in the treatment group (70.2 6 13.3 vs. 74.7 6 10.5 s),
this phase decreased in the placebo group (75.3 6 11.1 vs.
43.0 6 6.7 s, p , 0.05). Accordingly, the hyperemic perfusion,
determined by the area of the postocclusion perfusion tracing,
was significantly higher in the treatment group (1,867 6 350 vs.
3,310 6 52 arbitrary units-s, p , 0.05). No significant relation
was found between changes in the hyperemic response and
those in systolic blood pressure (r 5 20.23, p 5 0.3).
Figure 2. Mean changes in 24-h systolic (A) and diastolic blood
pressure (B) compared with 24-h measurements at day 12 postopera-
tively in heart transplant recipients treated with omega-3 fatty acids
(open bars, n 5 14) or placebo (hatched bars, n 5 14). *p , 0.01.
Figure 3. Twenty-four hour mean arterial blood pressure 12 days and 6
months after heart transplantation in the treatment (n 5 14) (A) and
placebo (n 5 14) (B) groups. Each circle represents a group mean, with
vertical bars indicating SEM. Threshold values (dashed lines) of 107 mm
Hg during the day and 93 mm Hg during the night were used to determine
area under the blood pressure curve, reflecting the hypertensive load.
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Laboratory values. The mean concentration of serum
phospholipid omega-3 fatty acids increased significantly in the
treatment group and remained unchanged in the placebo
group (Table 3). Triglycerides were significantly reduced in the
treatment group, whereas a significant increase in total choles-
terol and HDL cholesterol occurred in both groups. The
relation between the change in 24-h blood pressure and that in
serum phospholipids was studied in the treatment group. The
changes in 24-h systolic blood pressure were significantly
related to those in eciosapentaenoic and docosahexaenoic acid
taken together (r 5 20.69, p 5 0.01) (Fig. 4). In contrast, we
were unable to demonstrate a significant relation between
changes in the hyperemic response and changes in eicosapen-
taenoic and docosahexaenoic acid (r 5 0.21, p 5 0.3). Creat-
inine clearance improved in both groups, with an insignificantly
higher value in the treatment group (81 6 5 ml/min) than in
the placebo group (74 6 8 ml/min) by the end of the study. The
dose and trough concentration of cyclosporine and the dose of
prednisolone were not different at any time between the
groups (Table 4).
Discussion
Effects on blood pressure. Our study confirms previous
observations that most heart transplant recipients treated with
cyclosporine develop hypertension within 6 months postoper-
atively. Sequential 24-h ambulatory measurements during this
period revealed a consistent increase in blood pressure in the
placebo group. Systolic and diastolic blood pressure reached
levels of probable hypertension (11), and most patients needed
antihypertensive drug treatment. By the end of the study, the
hypotensive effect attributable to treatment with omega-3 fatty
acids was 19 mm Hg in systolic and 11 mm Hg in diastolic
blood pressure. Comparable to other studies in transplant
recipients (10,14), our results seem to exceed those obtained in
treatment with omega-3 fatty acids in essential hypertension
(8,9). Three of the five patients in need of antihypertensive
drug treatment demonstrated an increase in serum levels of
eicosapentaenoic and docosahexaenoic acid below the group
means. We also found a significant inverse relation between
the development of systolic hypertension and the increase in
serum omega-3 fatty acids. Bønaa et al. (15) also observed a
Figure 4. Relation between changes in systolic blood pressure and in
serum eicosapentaenoic (EPA) and docosahexaenoic acid (DHA)
during treatment with omega-3 fatty acids.
Table 2. Reactive Hyperemic Response Before and 6 Months After Heart Transplantation
Placebo Group (n 5 12) Treatment Group (n 5 13)
Before Tx
6 mo
After Tx Before Tx
6 mo
After Tx
Rest perfusion (AU) 58 6 9 89 6 9 71 6 8 78 6 9
Peak hyperemia (AU) 99 6 9 141 6 10* 101 6 9 124 6 6*
Time to recovery (s) 75.3 6 11.1 43.0 6 6.7* 70.2 6 13.3 74.7 6 10.5†
Perfusion debt
repayment area (AU)
3,146 6 670 1,867 6 350‡ 3,447 6 741 3,310 6 520†
*p , 0.05, ‡p , 0.01 versus preoperative values. †p , 0.05 versus 6-month placebo group value. Data presented are
mean value 6 SEM. AU 5 arbitrary units; Tx 5 transplantation.
Table 3. Serum Phospholipid Fatty Acids and Lipids Before and 6
Months After Heart Transplantation
Placebo Group
(n 5 14)
Treatment Group
(n 5 14)
Before
Tx
6 mo
After Tx
Before
Tx
6 mo
After Tx
Fatty acid (mg/liter)
EPA 38 6 6 43 6 8 27 6 6 100 6 10*†
DHA 105 6 10 121 6 10 77 6 7‡ 130 6 7*
Total cholesterol
(mg/dl)
208 6 19 290 6 16* 193 6 15 247 6 16*
HDL cholesterol
(mg/dl)
32 6 4 52 6 4* 30 6 3 52 6 5*
Triglycerides
(mg/dl)
183 6 11 197 6 31 181 6 29 124 6 27†§
*p , 0.01, §p , 0.05 versus preoperative values. †p , 0.05 versus 6-month
placebo group value. ‡p , 0.05 versus preoperative placebo group value. Data
presented are mean value 6 SEM. DHA 5 docosahexaenoic acid; EPA 5
eicosapentaenoic acid; HDL 5 high density lipoprotein; Tx 5 transplantation.
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similar relation for mean arterial pressure and omega-3 fatty
acids in their successful treatment of mild hypertensive pa-
tients. Although relatively few patients were studied, it is
conceivable that the observed reductions in blood pressure
depend on the increases in serum omega-3 fatty acids, also
among heart transplant recipients.
The differences in 24-h blood pressure between the two
groups observed at baseline were probably due to the relatively
few patients studied and is supported by the fact that patient
characteristics, cyclosporine dose and blood concentrations
were equal and that there were no clear reasons for an initial
blood pressure increase caused by treatment with omega-3
fatty acids.
There are somewhat conflicting data concerning the 24-h
profile of blood pressure in heart transplant recipients. Early
reports (16,17) suggested a blunted decline or even a rise in
nocturnal values. Our results agree with a normalization of the
circadian rhythm of blood pressure variability within months
after heart transplantation (18,19). The 24-h mean arterial
blood pressure profiles after 6 months show a reduction in
blood pressure load in the treatment group during both day
and night.
Reactive hyperemia and possible hypotensive mechanisms
of omega-3 fatty acids. Although the origin of cyclosporine-
induced hypertension may be multifactorial, recent reports
(2–5) suggest the vascular endothelium as the main site of
impaired vascular regulation. The reactive hyperemic response
has been shown (20) to depend on intact endothelial function
with an adequate production of vasoactive substances. Thus,
the flow-dependent vasodilation of human conduit arteries
assessed by a high precision echocardiographic Doppler device
has been suggested (21) as a reliable noninvasive test of
endothelial function. Applied in patients with severe heart
failure, the hyperemic response of radial artery and total
forearm blood flow is impaired (22,23). In our study, the peak
hyperemic responses improved significantly in both groups
after heart transplantation. However, although the treatment
group maintained the preoperative levels, both the duration of
the hyperemia and the perfusion debt repayment decreased
significantly in the placebo group. This finding is consistent
with our earlier finding (24) of lower perfusion values at the
mid to late phase of hyperemia during long-term follow-up in
heart transplant recipients. Detectable within 6 months post-
operatively, these results oppose data that demonstrate revers-
ible abnormal endothelium-dependent responses in heart fail-
ure after transplantation (25). Despite normalization of
cardiac output and decreased vascular and interstitial edema,
an otherwise withdrawal of vasoconstrictor tone might be
antagonized by cyclosporine.
In vitro models and animal studies of cyclosporine toxicity
(4,5) have found evidence of inhibition of nitric oxide–
mediated vasodilation. Two recent studies (21,26) used NG-
monomethyl-L-arginine, a selective blocker of nitric oxide
synthesis, before cuff occlusion, to examine the contribution
of nitric oxide in human reactive hyperemia. Both studies
demonstrated that peak hyperemia was of comparable levels,
with or without the blocker. However, significantly lower
blood flow levels at mid to late phases of the response
resulted in significantly lower flow debt repayment in the
NG-monomethyl-L-arginine group. Thus, when these results
are compared with those of our placebo group, cyclosporine-
treatment offers similarities to the NG-monomethyl-L-arginine
group in that maintainance of vasodilation is impaired. Fur-
thermore, treatment seems to counteract these responses,
indicating endothelial dysfunction. Fleischhauer et al. (27)
improved endothelial-dependent vasodilatory response in cor-
onary arteries of heart transplant recipients receiving cyclo-
sporine after supplementation with omega-3 fatty acids, most
likely due to increased release or activity of nitric oxide.
Although our study also indicates an improvement in endothe-
lial function and a hypotensive role of omega-fatty acids, we
were unable to find a significant correlation between improve-
ment in endothelial function and changes in serum levels of
omega-3 fatty acids or blood pressure. It remains uncertain
whether lack of such interrelation reflects our way of address-
ing endothelial function or whether omega-3 fatty acids possess
other undetected qualities of lowering blood pressure.
Cyclosporine therapy seems to induce changes in the pros-
taglandin profile, increasing the production of the vasocon-
strictor tromboxane A2 (28). In contrast, supplementation with
omega-3 fatty acids increases tromboxane A3 formation, coin-
ciding with a fall in tromboxane A2 together with a significant
increase in total prostacyclin levels, promoting a vasodilatory
effect (6). In two recent randomized, double-blind studies of
treatment with omega-3 fatty acids in 10 hypertensive heart
transplant recipients (10) and 33 cyclosporine-treated renal
Table 4. Cyclosporine Doses/Trough Values and Prednisolone Doses
Time After Tx
Cyclosporine Dose
(mg/kg body weight)
Cyclosporine
Concentration (ng/ml)
Prednisolone Dose
(mg/kg body weight)
Placebo Group Treatment Group Placebo Group Treatment Group Placebo Group Treatment Group
12 days 5.5 6 0.4 5.1 6 0.3 341 6 19 342 6 12 0.2 6 0.0 0.2 6 0.0
1 mo 4.8 6 0.3 5.0 6 0.4 368 6 15 348 6 22 0.2 6 0.0 0.2 6 0.0
2 mo 4.7 6 0.2 4.0 6 0.2 294 6 10 290 6 15 0.1 6 0.0 0.1 6 0.0
3 mo 4.1 6 0.2 4.3 6 0.2 265 6 12 230 6 16 0.1 6 0.0 0.1 6 0.0
6 mo 3.5 6 0.2 3.7 6 0.3 183 6 5 190 6 11 0.1 6 0.0 0.1 6 0.0
Data presented are mean value 6 SEM. Tx 5 transplantation.
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transplant recipients (14), a significant reduction in blood
pressure was achieved, and a possible beneficial change in the
prostaglandins was discussed. Although prostaglandins were
not actually measured in either of these studies, a possible
omega-3 fatty acid–induced vasodilation due to an improved
prostaglandin profile has been demonstrated in cyclosporine-
treated animals (29).
Because prostaglandins are endothelial factors that may
also regulate the mid to late phases of reactive hyperemia in
humans, although controversial findings exist (21,30), our
technique (without the preocclusive introduction of blocking
agents) is inadequate in determining the relative impact of
prostaglandins with nitric oxide. The hypotensive mechanisms
suggested are not mutually exclusive. The physiologic changes
induced may result from simultaneous operating factors, with a
net result of peripheral vasoconstriction due to endothelial
dysfunction. Other local vasoactive substances, such as aden-
osine and adenosine triphosphate–sensitive potassium chan-
nels, also seem to be involved in the reactive hyperemia (31,32)
and may play a significant role in altering the response.
However, we are unaware of studies dealing with interaction of
these factors with cyclosporine. Furthermore, a history of heart
failure and hypercholesterolemia might add to the develop-
ment of endothelial damage, otherwise induced by cyclospor-
ine. The multifactorial background of damage to the endothe-
lium leads to the potential application of omega-3 fatty acids in
these patients, supported by our finding of a hypotensive effect
exceeding that obtained in subjects with essential hypertension
(8,9).
Because of strong evidence of lipoproteins modulating
vascular reactivity (33), the improved endothelial-dependent
responses could be due to the lower levels of triglycerides in
the treatment group. However, although the reduction of
triglycerides with omega-3 fatty acids is well known, it is only
lowering of total or low density lipoprotein (LDL) cholesterol
that has a documented impact on endothelial function (34).
Chin and Dart (35) compared the lipid-lowering effect of
hydroxymethylglutaryl-coenzyme A reductase inhibition with
daily supplementation of 5.75 g of omega-3 fatty acids in
hypercholesterolemic subjects. The statin reduced LDL cho-
lesterol by nearly 40% and significantly improved the response
to endothelium-dependent relaxation. Restoration of endothe-
lial function was also demonstrated in the omega-3 fatty acids
group, despite unchanged levels of cholesterol and triglycer-
ides after only 4 weeks treatment. Thus, taking these results
into account with the fact that omega-3 fatty acids did not
lower cholesterol concentrations in our study, the hypotensive
effect is probably not linked to the reduction in triglycerides.
Conclusions. Prophylactic supplementation with 4 g daily
of omega-3 fatty acids lowers blood pressure in heart
transplant recipients, depending on increases in serum
eicosapentaenoic and docosahexaenoic acids. Improved vas-
cular reactivity in the treatment group, demonstrated by a
more pronounced response to forearm skin ischemia than in
the placebo group, indicates an endothelial protective effect
that may contribute to the hypotensive role of omega-3 fatty
acids.
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